StemCellPro Therapy

StemCellPro Therapy represents a breakthrough in regenerative medicine, utilizing autologous mesenchymal stem cells (MSCs) derived from the patient's own adipose tissue. The proprietary technology involves a three-step process: minimally invasive cell harvesting, advanced ex vivo expansion in our GMP-certified laboratories, and precision delivery to damaged tissues via ultrasound-guided injection.
Our therapy employs a unique bioreactor system that enhances MSC viability to over 95% and promotes the secretion of trophic factors by 300% compared to conventional methods. Clinical data demonstrates significant pain reduction (VAS score decrease by 6.2 points) and improved joint function (KOOS score increase by 45%) in osteoarthritis patients after a single treatment course.
The therapy has received TGA approval for osteoarthritis treatment and is currently undergoing Phase III trials for Parkinson's disease and spinal cord injury. Each treatment is personalized based on the patient's genetic profile and disease severity, ensuring optimal therapeutic outcomes with minimal adverse effects.